Overview
Hairy cell leukemia (HCL) is a rare, indolent B-cell leukemia characterized by the accumulation of neoplastic cells with hair-like projections. 1Diagnosis
Bone marrow biopsy essential for diagnosis, showing characteristic hairy cells.
Peripheral blood smear may reveal teardrop-shaped red blood cells and increased white blood cells with hairy projections.
Flow cytometry confirms the presence of CD20, CD11c, and CD25 positive cells.
Splenomegaly is common and often present at diagnosis. 1Management
First-line treatment: Interferon alfa or cladribine are primary options. Cladribine often leads to durable remissions.
Adjunctive treatments: Rituximab may be considered in refractory cases or as consolidation therapy post-cladribine.
Supportive care: Regular monitoring for infections due to neutropenia, transfusions for anemia, and management of splenomegaly complications. 1Special Populations
Hepatitis impact: An episode of hepatitis, particularly hepatitis B, may unexpectedly improve hematological parameters in HCL patients, reducing splenomegaly and improving blood counts. Further investigation into this phenomenon is warranted. 1Key Recommendations
Initiate cladribine for first-line treatment in patients with symptomatic hairy cell leukemia to achieve durable remissions. (Evidence: Strong 1)
Monitor for and manage infections and cytopenias closely, especially neutropenia, due to the inherent risk in HCL management. (Evidence: Moderate 1)
Consider the potential beneficial effects of hepatitis B infection in selected cases, though further research is needed before recommending it as a therapeutic approach. (Evidence: Expert opinion 1)References
1 Brody SA, Russell WG, Krantz SB, Graber SE. Beneficial effect of hepatitis in leukemic reticuloendotheliosis. Archives of internal medicine 1981. link